

Table 3. Crude and Adjusted Rate Ratios of Acute Myocardial Infarction for Current Use of Celecoxib and Rofecoxib according to Dose

Variable	Case-Patients	Controls	Adjusted* Rate Ratio (95% CI)
No use, n†	793	16 680	1.00 (reference)
Celecoxib			
Recipients, n	287	5598	
Low-dose use, n (%)‡	208 (72.5)	4176 (74.6)	0.98 (0.83–1.17)
High-dose use, n (%)§	79 (27.5)	1422 (25.4)	1.00 (0.78–1.29)
Rofecoxib			
Recipients, n	239	3708	
Low-dose use, n (%)‡	218 (91.2)	3485 (94.0)	1.21 (1.02–1.43)
High-dose use, n (%)§*	21 (9.8)	223 (6.0)	1.73 (1.09–2.76)

* Adjusted for age at index (continuous variable); sex, hypertension, coronary artery disease, cerebrovascular disease, peripheral vascular disease, congestive heart failure, diabetes, respiratory illness, gastrointestinal ulcer disease, thyroid disorders, depression/psychiatric illness, and cancer in the year preceding cohort entry; use of concomitant therapy, including antilipemic agents, anticoagulants, and low-dose aspirin in the year preceding cohort entry; health care utilization, including hospitalizations, outpatient visits to any physician, and outpatient cardiologist visits, in the year preceding the index date; number of different drugs taken, chronic disease score and Charlson index score in the year preceding the index date; and past use of nonsteroidal anti-inflammatory drugs.

† No use in the year preceding the index date.

‡ ≤ 200 mg/d and ≤ 25 mg/d for celecoxib and rofecoxib, respectively.

§ >200 mg/d and >25 mg/d for celecoxib and rofecoxib, respectively.